GlassScriptPhysician profile
David Edward Tapke
NPI 1033523253
$17,132.13
in general payments reported to CMS, 2019-2025
40 companies · $6,161 in 2025
The $6,161 reported for 2025 was more than what 85% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,303 · 2020: $947 · 2021: $1,329 · 2022: $1,514 · 2023: $2,560 · 2024: $3,318 · 2025: $6,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $1,502 · Education: $210 · Travel and Lodging: $15.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,311.73 |
| Consulting Fee | $1,502.07 |
| Education | $209.82 |
| Travel and Lodging | $15.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,905.20 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,316.36 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,313.06 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $1,005.09 | 2022-2025 | Tezspire |
| Allerderm Laboratories | $1,000.00 | 2019 | |
| Grifols USA, LLC | $920.51 | 2020-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Novartis Pharmaceuticals Corporation | $766.89 | 2019-2025 | |
| Pfizer INC. | $647.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $618.41 | 2020-2025 | Cuvitru, Gattex |
| Alk-Abello, INC | $309.59 | 2019-2025 | Alternaria Tenuis, Timothy, Standardized, Standardized Mite D. Farinae |
| Octapharma USA, INC. | $306.45 | 2021-2025 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Optinose US, INC. | $277.83 | 2019-2024 | |
| Abbvie INC. | $270.28 | 2022-2025 | Rinvoq |
| Blueprint Medicines Corporation | $248.74 | 2023-2025 | Ayvakit |
| Csl Behring | $234.44 | 2023-2025 | Hizentra, Privigen |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tapke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.